FDA Approves First Oral Drug for Dermatomyositis
The US FDA has approved Lisraya (brepocitinib) tablets for treating dermatomyositis in adults, marking the approval of the first oral drug for this indication.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed